
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
TrialAssure has announced the launch of TrialAssure REGISTRY 2.5. REGISTRY 2.5 lets users manage the entire disclosure process from start to finish, including registry assessments, validation and quality checks, review cycles, approvals, and comments from regulatory authorities.
Get more information







